Mozenavir

Mozenavir
Clinical data
Trade names	Mozenavir
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name (4R,5S,6S,7R)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;
CAS Number	174391-92-5;
PubChem CID	154044;
ChemSpider	135759;
UNII	64OO8946ER;
CompTox Dashboard (EPA)	DTXSID40169822 ;
Chemical and physical data
Formula	C33H36N4O3
Molar mass	536.7 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC(=CC=C3)N)CC4=CC(=CC=C4)N)CC5=CC=CC=C5)O)O;
	InChI InChI=1S/C33H36N4O3/c34-27-15-7-13-25(17-27)21-36-29(19-23-9-3-1-4-10-23)31(38)32(39)30(20-24-11-5-2-6-12-24)37(33(36)40)22-26-14-8-16-28(35)18-26/h1-18,29-32,38-39H,19-22,34-35H2/t29-,30-,31+,32+/m1/s1; Key:KYRSNWPSSXSNEP-ZRTHHSRSSA-N;

Mozenavir (DMP-450) is an antiviral drug which was developed as a treatment for HIV/AIDS. It acts as an HIV protease inhibitor and binds to this target with high affinity,^[1]^[2] however despite promising results in early testing,^[3]^[4] mozenavir was unsuccessful in human clinical trials. Studies continue into related derivatives.^[5]

References

↑ Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, et al. (May 1996). "Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors". Journal of Medicinal Chemistry. 39 (11): 2156–69. doi:10.1021/jm960083n. PMID 8667359.
↑ Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP (April 1998). "The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues". Bioorganic & Medicinal Chemistry Letters. 8 (7): 823–8. doi:10.1016/s0960-894x(98)00119-x. PMID 9871548.
↑ De Clercq E (April 2002). "Highlights in the development of new antiviral agents". Mini Reviews in Medicinal Chemistry. 2 (2): 163–75. doi:10.2174/1389557024605474. PMID 12370077.
↑ Hensen C, Hermann JC, Nam K, Ma S, Gao J, Höltje HD (December 2004). "A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors". Journal of Medicinal Chemistry. 47 (27): 6673–80. doi:10.1021/jm0497343. PMID 15615516.
↑ Li P, Wang S, Wang H, Yan H (2019). "2-Symmetric HIV-1 Protease Inhibitors and Docking Study". Biological & Pharmaceutical Bulletin. 42 (2): 261–267. doi:10.1248/bpb.b18-00705. PMID 30713256.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid8667359-1] Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, et al. (May 1996). "Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors". Journal of Medicinal Chemistry. 39 (11): 2156–69. doi:10.1021/jm960083n. PMID 8667359.

[pmid9871548-2] Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP (April 1998). "The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues". Bioorganic & Medicinal Chemistry Letters. 8 (7): 823–8. doi:10.1016/s0960-894x(98)00119-x. PMID 9871548.

[pmid12370077-3] De Clercq E (April 2002). "Highlights in the development of new antiviral agents". Mini Reviews in Medicinal Chemistry. 2 (2): 163–75. doi:10.2174/1389557024605474. PMID 12370077.

[pmid15615516-4] Hensen C, Hermann JC, Nam K, Ma S, Gao J, Höltje HD (December 2004). "A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors". Journal of Medicinal Chemistry. 47 (27): 6673–80. doi:10.1021/jm0497343. PMID 15615516.

[pmid30713256-5] Li P, Wang S, Wang H, Yan H (2019). "2-Symmetric HIV-1 Protease Inhibitors and Docking Study". Biological & Pharmaceutical Bulletin. 42 (2): 261–267. doi:10.1248/bpb.b18-00705. PMID 30713256.

[1]

[2]

[3]

[4]

[5]